Combination Chemotherapy for Lung Cancer
Author Information
Author(s): Stathopoulos G P, Dimitroulis J, Antoniou D, Katis C, Tsavdaridis D, Armenaki O, Marosis C, Michalopoulou P, Grigoratou T, Stathopoulos J
Primary Institution: Errikos Dunant Hospital, Athens, Greece
Hypothesis
The study aimed to determine the efficacy of irinotecan plus paclitaxel in untreated patients with advanced non-small-cell lung cancer (NSCLC).
Conclusion
Irinotecan combined with paclitaxel, administered every 2 weeks, appears to be an effective treatment for advanced-stage NSCLC.
Supporting Evidence
- 19 out of 46 evaluable patients achieved a partial response, indicating effectiveness.
- The median duration of response was 6 months.
- Adverse reactions included myelotoxicity in 19.2% of patients.
Takeaway
This study tested a new medicine combination to help people with a serious type of lung cancer, and it worked pretty well.
Methodology
The study involved administering irinotecan and paclitaxel to patients every 2 weeks for a planned number of nine cycles, with dose adjustments based on tolerance.
Limitations
The study had a small sample size and was limited to patients with specific eligibility criteria.
Participant Demographics
The median age of participants was 65 years, with 83.9% male and 16.1% female.
Statistical Information
Confidence Interval
95% CI for dose intensity was 65.1–67.2 mg/m²/week for paclitaxel and 58.3–59.8 mg/m²/week for irinotecan.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website